Intravenous rhythm control for pediatric patients
Sotalol IV offers benefits for pediatric drug therapy.
Fast Onset
Facilitates timely evaluation of therapeutic response, to support clinical decision-making
Linear Kinetics
Allows for predictable dosing, simplified dose adjustment, and smooth transition to oral therapy
Short Half-Life
Enables prompt discontinuation and transition to alternative treatment strategies
Intravenous Infusion
Offers controlled delivery and less variability in absorption compared to oral dosing alone
Sotalol is an antiarrhythmic indicated for...
The maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)) in adults and pediatric patients with highly symptomatic AFIB/AFL who are currently in sinus rhythm.
Limitations of use: Avoid use in patients with minimally symptomatic or easily reversible AFIB/AFL.The treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia in adult and pediatric patients.
Limitations of use: Sotalol has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.
Connect with the AltaThera team.
Contact us today
We're here to answer your questions about intravenous sotalol, assist in staff training, and more, virtually or in-person.
Send us a messageREFERENCES
1 Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 07/2025.
2 BetaPace AF (sotalol hydrochloride) [Full Prescribing Information]. Zug, CH: Covis Pharma; 06/2023.